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Obesity is a serious health problem that is caused by an equilibrium shift towards elevated energy intake over 
expenditure, and is often involved in a range of metabolic diseases. A diet rich in saturated fatty acids (SFA), 
which is one of the leading causes of obesity and ectopic lipid accumulation in the key organs for metabolic 
regulation, results in an imbalance of the cellular metabolism and an inadequate response of hepatocytes to 
insulin, which is known as hepatic insulin resistance. Although endogenous non-coding small microRNAs 
(miRNAs) play important roles in the post-transcriptional repression of the target genes, the implications of 
obesity-induced miRNAs in metabolic diseases, particularly in the development of hepatic insulin resistance, are 
largely unknown. In recent studies, SFA and a high fat diet were found to increase the expression of certain 
miRNAs significantly in the liver and skeletal muscle. These obesity-induced miRNAs were also up-regulated in 
human subjects with metabolic diseases. Our recent study highlights a novel mechanism whereby miR-96, which 
is one of the obesity-induced miRNA, participates actively in the development of hepatic insulin resistance in 
obesity. Studies focusing on obesity-induced miR-96 have indicated the strong diagnostic and therapeutic 
importance of miRNAs in insulin resistance and metabolic diseases. This will also help better understand the 
pathogenesis of insulin resistance and T2DM in obesity, and enable the development of inhibitors against 
obesity-induced miRNAs as a novel diagnostic and therapeutic strategy for metabolic diseases. 
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Obesity is a serious global health problem resulting from 
an equilibrium-shift towards elevated energy intake over 
expenditure, and has been suggested to be involved in the 
development of a range of metabolic diseases, such as 
hypertension, dyslipidemia, and type 2 diabetes (T2DM) [1, 2]. 
A diet rich in saturated fatty acids (SFA), which is one of 
leading causes of obesity and ectopic lipid accumulation in 
the liver, causes an imbalance of the cellular metabolism that 
can lead to an inadequate response of hepatocytes to insulin, 
also known as hepatic insulin resistance [3, 4]. Accumulating 
evidence has indicated the molecular mechanisms underlying 
the hepatic insulin resistance induced by SFA and obesity, 
such as the overburden of ceramide and diacylglycerol 
(DAG), increased oxidative stress, inflammation, and 
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mitochondrial dysfunction [5, 6]. On the other hand, despite 
the impressive progress with sophisticated investigation, the 
precise mechanisms for how SFA causes hepatic insulin 
resistance is not completely understood.  
MicroRNAs (miRNAs) consist of approximately 
20-25-nucleotides and are highly conserved naturally 
occurring, small non-coding RNA molecules that regulate the 
expression of the target genes at the post-transcriptional level 
[7]. In general, miRNAs bind to the 3’ untranslated regions 
(3’UTRs) of the specific target mRNAs, thereby causing 
either mRNA degradation or translational suppression of 
their target genes [7]. Extensive studies have suggested that 
miRNAs are negatively involved in the expression of a 
variety of genes in both normal and pathological states, and 
the inappropriate regulation of miRNAs expression is linked 
to the pathogenesis of many diseases, such as proliferative, 
degenerative, and metabolic diseases [7, 8]. Following the 
discovery that miRNA plays a key role in the amino acid 
catabolism [9], many studies have reported miRNAs to be 
important regulators of the hepatic lipid and glucose 
homeostasis, whose impairment is linked to the 
pathophysiology of insulin resistance and T2DM [10, 11]. 
Recently, the expression of certain miRNAs targeting the 
molecules transducing insulin signaling are regulated 
aberrantly in SFA-induced obesity, and linked intimately to 
the pathogenesis of hepatic insulin resistance [10, 12-15]. 
Furthermore, a high fat diet (HFD) appears to impair hepatic 
insulin signaling in mice, concomitant with the induction of 
specific miRNAs targeting the insulin signaling molecules in 
the liver [12, 16]. Although there have been many advances in 
studies of the implication of miRNAs in the metabolism, the 
emerging mechanisms for how obesity-induced miRNAs are 
responsible for the regulatory roles in hepatic insulin 
resistance are unclear.  
A recent study suggested that the expression of certain 
miRNAs targeting the mRNAs of insulin signaling molecules 
is modulated aberrantly in HFD- or SFA-induced obesity, 
leading to insulin resistance in hepatocytes [17]. Using 
miRNA expression profiling based on an Affymetrix miRNA 
array, the miRNAs whose expressions are affected by the 
development of HFD-induced insulin resistance were 
identified [17]. Followed by PicTar and TargetScan analysis, 
the miRNAs that are expected to target 3’UTR of INSR were 
identified and classified because impaired insulin signaling 
by HFD can be attributed most likely to the reduction of 
INSR and its downstream target, IRS-1, in the insulin 
signaling cascade. Twenty miRNAs were selected initially as 
miRNAs presumably targeting 3’UTR of the INSR gene for 
further experiments based on their targeting score to the 
3’UTR of INSR, as well as expression abundancy and 
reliability of the results from the Affymetrix miRNA array. 
As expected, certain miRNAs, including miR-96, miR-140, 
miR-151, miR-185, miR-455, miR-532, and miR-874 etc., 
which are presumably targeting 3’UTRs of INSR, were 
increased (> 1.5-fold) in the liver of HFD mice [17]. This is 
consistent with other independent studies based on 
obese-type insulin resistance mice models [12, 16, 18-20]. 
Therefore, these upregulated miRNAs are regarded as 
potential candidate miRNAs for suppressing INSR 
expression, but none of these have been validated and 
confirmed to suppress the expression of INSR by targeting 
the 3’UTR of INSR.  
Although the induction of miR-96 in the liver of HFD-fed 
mice and SFA-treated hepatocytes was reported, there are 
few reports on the differential expression of miR-96. Similar 
to previous results, miR-96 was upregulated in the liver of 
NAFLD patients [21] and obese diabetic animal models, such 
as ob/ob and db/db mice [22, 23]. In addition, miR-96 was 
increased in the liver of mice after an injection of resistin [24], 
an adipokine associated with obesity-mediated insulin 
resistance and T2DM [25]. Interestingly, the plasma level of 
resistin was higher in the HFD-fed mice and its inhibition 
ameliorated the HFD-induced hepatic insulin resistance [26]. 
Previous studies suggested an increase in miR-96 as a 
contributor to the development of hepatic insulin resistance 
induced by obesity. The SFA-enriched HFD caused an 
impairment of insulin signaling by the reduction of INSR and 
IRS-1 expression with the concomitant upregulation of 
miR-96 in the mice liver, and the 3’UTRs of INSR and IRS-1 
were suggested to be a potential target of miR-96 from the in 
silico target analysis. Therefore, a previous study [17] focused 
on miR-96 to further determine its functional significance in 
hepatic insulin resistance. 
Hsa-miR-96 is located on human chromosome 7q32.2 and 
belongs to the miR-183 family, which is comprised of three 
conserved miRNAs (miR-96, miR-182 and miR-183) in 
various animals [27]. Accumulating evidence suggests that 
members of the miR-183 family with strong sequence 
similarity play crucial roles in a wide range of normal 
processes and pathological conditions, such as cell growth, 
differentiation, apoptosis, immunity, sensing, and 
metabolism [27-29]. Among them, miR-96 is involved mainly 
in oncogenesis and cancer progression in various types of 
tissues and organs, including the liver, stomach, and breast 
cancer [29-31]. Therefore, miR-96 is acknowledged as an 
oncogenic miRNA that facilitates the development of cancers 
by promoting the proliferation and survival of the malignant 
cells [32, 33]. Recent studies have shown that miR-96 also 
regulates the expression of many of the genes involved in the 
metabolism, including in lipid homeostasis and adipogenesis. 
The role of miR-96 in the metabolism was first unveiled in 
the regulation of insulin secretion from pancreatic β-cells [34]. 
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Lovis P. et al. reported that insulin secretion was impaired 
substantially by miR-96, which increases the expression of 
granuphilin, a negative modulator of insulin exocytosis, and 
suppresses the expression of Noc2, a key player in insulin 
secretion, from pancreatic β-cells [34]. This suggests that 
miR-96 is involved in the regulation of insulin exocytosis, 
working as an important modulator in the optimal insulin 
secretory capacity. The importance of miR-96 in the 
regulation of lipid homeostasis was also reported. miR-96 
increases lipid synthesis and adipogenesis in the mouse liver 
by downregulating INSIG-2, a regulatory molecule for 
retaining the SREBP-precursor in the ER [35]. In addition, 
miR-96 also plays an important role in the cholesterol 
metabolism by targeting hepatic scavenger receptor class B 
type I (SR-BI) directly, which promotes the selective 
high-density lipoprotein cholesterol (HDL-C) uptake [36].  
The former study showed that the roles and effects of 
miR-96 in insulin resistance resulted from a mitochondrial 
dysfunction [37]. Interestingly, miR-96 was found to be 
upregulated by the mitochondrial dysfunction and associated 
with impaired insulin signaling in SK-Hep1 cells, suggesting 
its role in insulin signaling and insulin resistance [37]. The 
most important finding from our recent study is that 
obesity-induced miR-96 is linked causally to the impaired 
insulin signaling and glycogen metabolism through the 
down-regulation of INSR and IRS-1 in hepatocytes. miR-96 
targets the 3’UTRs of INSR and IRS-1 directly and 
down-regulates the expression of INSR and IRS-1 at the 
post-transcriptional level. The ectopic expression of miR-96 
impairs insulin signaling and the insulin-stimulated synthesis 
of glycogen in hepatocytes via the post-transcriptional 
repression of INSR and IRS-1. Therefore, our study unveiled 
a novel mechanism where miR-96 participates actively in the 
pathogenesis of hepatic insulin resistance. Moreover, the 
upregulation of miR-96 by SFA is proposed as a casual 
factor in the pathogenesis of hepatic insulin resistance. 
The underlying mechanism for how the expression of 
miR-96 is upregulated by SFA or HFD is not completely 
understood. Although there is insufficient evidence 
elucidating the molecular mechanism underlying the 
regulation of miR-96 expression in the liver by obesity, the 
induction of miR-96 might be initiated by certain 
transcription factors activated by palmitate or a HFD in 
hepatocytes. Therefore, the transcription factor binding sites 
on the promoter of miR-96 were predicted further by in silico 
analysis because several tentative transcription factors 
activated by obesity or HFD might bind to the specific 
binding sites on the promoter. This type of analysis allows a 
Figure 1. Implication of obesity-induced miR-96 in hepatic insulin resistance. 
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prediction of several potential mechanisms that could 
contribute to the induction of miR-96 in obesity. Among the 
handful of transcription factors identified to be activated by a 
HFD or obesity, the intensely studied transcription factors 
have been SREBPs, PPARγ, and C/EBPα. SREBPs play a 
key role in the biosynthesis of fatty acids and cholesterol, 
and their activation is associated closely with diabetic fatty 
liver and hyperlipidemia [38]. A recent study showed that 
SREBP targets the promoter of miR-96 on mouse 
chromosome 6 directly [35]. Furthermore, miR-96 can 
increase the nuclear translocation of SREBPs and lipid 
synthesis rapidly in a mouse liver via the suppression of 
INSIG-2, a key molecule for retaining the SREBP-SCAP 
complex in the ER [35]. Therefore, the induction of miR-96 by 
palmitate or HFD reported in a previous study [17] is most 
likely to be caused by the activation of SREBPs, suggesting 
that the activation of SREBPs by SFA is a substantial 
induction mechanism of miR-96 expression in the liver. 
Similar to the role of SREBPs, PPARγ also has been shown 
to be an important nuclear receptor protein that regulates the 
expression of several genes involved in the lipid metabolism 
and lipid biosynthesis [39]. Based on the global expression 
analysis of miRNAs, miR-96 was upregulated in 
differentiating 3T3-L1 adipocytes by PPARγ activation [40]. 
PPARγ was found to colocalize with C/EBPα [41], which is 
also found as an adipogenic transcription factor activated by 
HFD [42]. The activation of PPARγ facilitated with C/EBPα 
could play a substantial regulatory role for an increase in 
miR-96 in the liver under obese conditions. In addition, 
XBP1 is activated by ER stress, such as a HFD and obesity, 
and activates the expression of C/EBPα by binding to its 
specific sites located on the promoter [43, 44]. Therefore, 
further study is warranted, but miR-96 might be a key 
regulator in the vicious cycle between hepatic lipid 
accumulation and insulin resistance. Several lines of 
evidence imply the upregulation of miR-96 through 
XBP1-dependent mechanisms under ER stress-induced by 
HFD. 
In summary, Fig. 1 presents a possible mechanism for how 
obesity-induced miR-96 is implicated in the development of 
hepatic insulin resistance. An excess amount of dietary SFA 
or palmitate triggers various stresses generating retrograde 
signals to the nucleus [45]. These signals regulate several 
corresponding kinases, and subsequently certain transcription 
factors that are influenced by a retrograde signal may induce 
the production and processing of obesity-induced miRNAs 
targeting the 3’UTR of INSR or IRS-1, leading to impaired 
insulin signaling and hepatic insulin resistance by 
suppressing the expression of INSR or IRS-1. Further studies 
of the signals and transcription factors involved and how 
they modulate obesity-induced miRNAs and 
miRNA-mediated insulin resistance will be the next 
interesting challenge. Over the past decade, the prognostic 
and therapeutic importance of obesity-induced miRNAs in 
insulin resistance and T2DM have been suggested from solid 
molecular evidence. These studies revealed the novel role of 
obesity-induced miR-96 as a causal factor for hepatic insulin 
resistance. Overall, miR-96 can target a range of genes, in 
which each gene can be regulated by several other metabolic 
regulators. Studies of the regulation mechanism in miR-96 
and other obesity-induced miRNAs as well as their crosstalk 
with key metabolic regulators are currently underway. It will 
increase the knowledge of the pathogenesis of 
obesity-induced insulin resistance and T2DM, and enable the 
discovery of miRNAs as clinically potential diagnostic and 
therapeutic applications. In addition, global expression 
analysis of miR-96 and other obesity-induced miRNAs in 
body fluids, such as urine and blood, will also facilitate the 
development of new diagnostic strategies for metabolic 
disease.  
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